234 related articles for article (PubMed ID: 31302238)
1. Glycine transporter inhibitors: A new avenue for managing neuropathic pain.
Al-Khrasani M; Mohammadzadeh A; Balogh M; Király K; Barsi S; Hajnal B; Köles L; Zádori ZS; Harsing LG
Brain Res Bull; 2019 Oct; 152():143-158. PubMed ID: 31302238
[TBL] [Abstract][Full Text] [Related]
2. Long-term application of glycine transporter inhibitors acts antineuropathic and modulates spinal N-methyl-D-aspartate receptor subunit NR-1 expression in rats.
Barthel F; Urban A; Schlösser L; Eulenburg V; Werdehausen R; Brandenburger T; Aragon C; Bauer I; Hermanns H
Anesthesiology; 2014 Jul; 121(1):160-9. PubMed ID: 24598217
[TBL] [Abstract][Full Text] [Related]
3. Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain.
Dohi T; Morita K; Kitayama T; Motoyama N; Morioka N
Pharmacol Ther; 2009 Jul; 123(1):54-79. PubMed ID: 19393690
[TBL] [Abstract][Full Text] [Related]
4. Glycine transporter GlyT1, but not GlyT2, is expressed in rat dorsal root ganglion--Possible implications for neuropathic pain.
Schlösser L; Barthel F; Brandenburger T; Neumann E; Bauer I; Eulenburg V; Werdehausen R; Hermanns H
Neurosci Lett; 2015 Jul; 600():213-9. PubMed ID: 26101830
[TBL] [Abstract][Full Text] [Related]
5. Spinal antiallodynia action of glycine transporter inhibitors in neuropathic pain models in mice.
Morita K; Motoyama N; Kitayama T; Morioka N; Kifune K; Dohi T
J Pharmacol Exp Ther; 2008 Aug; 326(2):633-45. PubMed ID: 18448867
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Glycine Re-Uptake: A Potential Approach for Treating Pain by Augmenting Glycine-Mediated Spinal Neurotransmission and Blunting Central Nociceptive Signaling.
Cioffi CL
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34200954
[TBL] [Abstract][Full Text] [Related]
7. Activity of novel lipid glycine transporter inhibitors on synaptic signalling in the dorsal horn of the spinal cord.
Winters BL; Rawling T; Vandenberg RJ; Christie MJ; Bhola RF; Imlach WL
Br J Pharmacol; 2018 Jun; 175(12):2337-2347. PubMed ID: 29500820
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological Evidence on Augmented Antiallodynia Following Systemic Co-Treatment with GlyT-1 and GlyT-2 Inhibitors in Rat Neuropathic Pain Model.
Mohammadzadeh A; Lakatos PP; Balogh M; Zádor F; Karádi DÁ; Zádori ZS; Király K; Galambos AR; Barsi S; Riba P; Benyhe S; Köles L; Tábi T; Szökő É; Harsing LG; Al-Khrasani M
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33804568
[TBL] [Abstract][Full Text] [Related]
9. Role of glial and neuronal glycine transporters in the control of glycinergic and glutamatergic synaptic transmission in lamina X of the rat spinal cord.
Bradaïa A; Schlichter R; Trouslard J
J Physiol; 2004 Aug; 559(Pt 1):169-86. PubMed ID: 15235081
[TBL] [Abstract][Full Text] [Related]
10. Role of the spinal cord NR2B-containing NMDA receptors in the development of neuropathic pain.
Qu XX; Cai J; Li MJ; Chi YN; Liao FF; Liu FY; Wan Y; Han JS; Xing GG
Exp Neurol; 2009 Feb; 215(2):298-307. PubMed ID: 19046970
[TBL] [Abstract][Full Text] [Related]
11. Antinociceptive effect of intracerebroventricular administration of glycine transporter-2 inhibitor ALX1393 in rat models of inflammatory and neuropathic pain.
Takahashi Y; Hara K; Haranishi Y; Terada T; Obara G; Sata T
Pharmacol Biochem Behav; 2015 Mar; 130():46-52. PubMed ID: 25579325
[TBL] [Abstract][Full Text] [Related]
12. Positive N-methyl-D-aspartate receptor modulation by selective glycine transporter-1 inhibition in the rat dorsal spinal cord in vivo.
Whitehead KJ; Pearce SM; Walker G; Sundaram H; Hill D; Bowery NG
Neuroscience; 2004; 126(2):381-90. PubMed ID: 15207356
[TBL] [Abstract][Full Text] [Related]
13. Contribution of the spinal cord BDNF to the development of neuropathic pain by activation of the NR2B-containing NMDA receptors in rats with spinal nerve ligation.
Geng SJ; Liao FF; Dang WH; Ding X; Liu XD; Cai J; Han JS; Wan Y; Xing GG
Exp Neurol; 2010 Apr; 222(2):256-66. PubMed ID: 20079352
[TBL] [Abstract][Full Text] [Related]
14. Lessons from the knocked-out glycine transporters.
Gomeza J; Armsen W; Betz H; Eulenburg V
Handb Exp Pharmacol; 2006; (175):457-83. PubMed ID: 16722246
[TBL] [Abstract][Full Text] [Related]
15. Blockade of glycine transporter (GlyT) 2, but not GlyT1, ameliorates dynamic and static mechanical allodynia in mice with herpetic or postherpetic pain.
Nishikawa Y; Sasaki A; Kuraishi Y
J Pharmacol Sci; 2010; 112(3):352-60. PubMed ID: 20173309
[TBL] [Abstract][Full Text] [Related]
16. BDNF contributes to the development of neuropathic pain by induction of spinal long-term potentiation via SHP2 associated GluN2B-containing NMDA receptors activation in rats with spinal nerve ligation.
Ding X; Cai J; Li S; Liu XD; Wan Y; Xing GG
Neurobiol Dis; 2015 Jan; 73():428-51. PubMed ID: 25447233
[TBL] [Abstract][Full Text] [Related]
17. Electrophysiological evidence of increased glycine receptor-mediated phasic and tonic inhibition by blockade of glycine transporters in spinal superficial dorsal horn neurons of adult mice.
Oyama M; Kuraoka S; Watanabe S; Iwai T; Tanabe M
J Pharmacol Sci; 2017 Mar; 133(3):162-167. PubMed ID: 28302446
[TBL] [Abstract][Full Text] [Related]
18. NMDA receptor 2B subunit-mediated synaptic transmission in the superficial dorsal horn of peripheral nerve-injured neuropathic mice.
Iwata H; Takasusuki T; Yamaguchi S; Hori Y
Brain Res; 2007 Mar; 1135(1):92-101. PubMed ID: 17198690
[TBL] [Abstract][Full Text] [Related]
19. Effect of NMDA NR2B antagonist on neuropathic pain in two spinal cord injury models.
Kim Y; Cho HY; Ahn YJ; Kim J; Yoon YW
Pain; 2012 May; 153(5):1022-1029. PubMed ID: 22424878
[TBL] [Abstract][Full Text] [Related]
20. N-methyl D-aspartate receptor subtype 2B antagonist, Ro 25-6981, attenuates neuropathic pain by inhibiting postsynaptic density 95 expression.
Huang LE; Guo SH; Thitiseranee L; Yang Y; Zhou YF; Yao YX
Sci Rep; 2018 May; 8(1):7848. PubMed ID: 29777135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
